Expression and identification of immunological activities of the HIV-gp120N-human interferon gamma fusion protein

Anatomical Record

Volumn 292, Issue 3, 2009, Pages 381-386

  Feng, Ting Ting ^a   Zhao, Gang ^a   Yao, Hang Ping ^a   Wang, Qiao Ping ^a   Wu, Nan Ping ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

HIV gp120N; Immune adjuvant; Interferon c; Recombinant expression

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 120 GAMMA INTERFERON FUSION PROTEIN; HYBRID PROTEIN; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 2; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BACTERIAL CELL; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FEMALE; GENE IDENTIFICATION; GENE ISOLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNIZATION; LYMPHOCYTE PROLIFERATION; MALE; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT PLASMID; SPLEEN CELL; TH1 CELL; TH2 CELL;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL PROLIFERATION; CYTOKINES; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HIV ENVELOPE PROTEIN GP120; HUMANS; IMMUNIZATION; INTERFERON-GAMMA; LYMPHOCYTE ACTIVATION; MALE; MICE; MICE, INBRED BALB C; PLASMIDS; RECOMBINANT FUSION PROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TH2 CELLS;

HUMAN IMMUNODEFICIENCY VIRUS 1; MUS; PROKARYOTA;

EID: 65549086714     PISSN: 19328486     EISSN: 19328494     Source Type: Journal    
DOI: 10.1002/ar.20853     Document Type: Article

References (23)

1. Billaut-Mulot O, Idziorek T, Ban E, et al. 2000. Interleukin-18 modulates immune responses induced by HIV-1 nef DNA prime/protein boost vaccine. Vaccine 19:95-102.
2. Billaut-Mulot O, Idziorek T, Loyens M, et al. 2001. Modulation of cellular and humoral immune responses to amultiepitopic HIV-1 DNA vaccine by interleukin-18 DNA immunization/viral protein boost. Vaccine 19:2803-2811.
3. Chen C, Qian L, Zhong WJ, et al. 2001. The identification of recombinant gp120 surface antigen expression, purification and immunological. Virologica Sinica 16:109-113.
4. Davis HL, Brazlot Millan CL, Mancini M, et al. 2003. DNA-based immunization against hepatitis B surface antigen in normal and HbsAg transgentic mice. Vaccine 15:849-852.
5. Feng Y, Fu L-C, Zhang F-X. 2005. The latest mouse model of AIDS immunology research progress. Prog Microbiol Immunol 33:87-89.
6. García Tuñón I, Ricote M, et al. 2007. Influence of IFN-gamma and its receptors in human breast cancer. BMC Cancer 7:158.
7. Gorse GJ, Simionescu, Gira BP, et al. 2006. Cellular immune responses in asymptomatic Human Immunodeficiency Virus Type 1 (HIV-1) Infection and effects of Vaccination with recombinant envelope glycoprotein of HIV-1. Clin Vaccine Immunol 5:26-32.
8. Jobes DV, Daoust M, Nguyen VT, et al. 2006. Longitudinal population analysis of dual infection with recombination in two strains of HIV Type 1 subtype B in an individual from a Phase 3 HIV vaccine efficacy trial. AIDS Res Hum Retroviruses 22:968-978.
9. Joos B, Trkola A, Kuster H, et al. 2006. Long-Term multiple-dose pharmacokinetics of Human Monoclonal Antibodies (MAbs) against Human immunodeficiency virus Type 1 envelope gp120 (MAb 2G12) and gp41 (MAbs 4E10 and 2F5). Antimicrob Agents Chemother 5:1773-1779.
10. Kalams SA. 2003. Cellar immunity for prevention and clearance of HIV infection. Curr Mol Med 3:195-198.
11. Kent SJ, Zhao A, Dale CJ, et al. 2000. A recombinant avipoxvirus HIV-1 vaccine expressing interferon-gamma is safe and immunogenic in macaques. Vaccine 18:2250-2553.
12. Kim JJ, Yang JS, Manson KH, et al. 2001. Modulation of Antigenspecific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-gamma, or IL-4 gene adjuvant. Vaccine 19:2496-2505.
13. Kim JJ, Yang JS, Montaner L, et al. 2000. Coimmunization with IFN-gamma or IL-1, but not IL-13 or IL-4 cDNA can enhance Th1-type DNA vaccine-induced immune responses in vivo. J Interferon Cytokine Res 20:311-319.
14. Kusakabe K-I, Xin K-Q, Katoh H, et al. 2000. The timing of GMCSF expression plasmid administration influences the Th1/Th2 response induced by an HIV-1-Specific DNA Vaccine. J Immunol 164:3102-3111.
15. Lusso P. 2006. HIV and the chemokine system: 10 years later. EMB J 25:447-456.
16. Pan J, Heiser A, Marget M, Steinmann J, Kabelitz D. 2005. Enhanced antimetastatic effect of fetal liver kinase 1 extracellular domain and interferon-gamma fusion gene-modified dendritic cell vaccination. Gene Ther 12:742-750.
17. Rits-Volloch S, Frey G, et al. 2006. Restraining the conformation of HIV-1 gp120 by removing a flexible loop. EMBO J 25:5026-5035.
18. Seddiki N, Santner-Nanan B, et al. 2006. Persistence of naïve CD45RA+ regulatory T cells in adult life. Blood 107:2830-2838.
19. Xiang WF, Tao SY. 2003. The effect of adjuvant Cytokines to HIV DNA vaccine immunity. Cell Mol J Immunol 19:620-622.
20. Xu R-H, Zheng L-Y, He D-L, et al. 2008. Effect of fragile histidine triad gene transduction on proliferation and apoptosis of human hepatocellular carcinoma cells. World J Gastroenterol 14:3754-3758.
21. Yu ZY, Zhang LH, Yao HP, Yang XH. 2005. Construction of the eukaryotic expression vector containing rat transforming growth factor beta type II receptor and interferon gamma fusion genes. J Zhejiang Univ (Med Sci) 34:43-47.
22. Zheng J-W, Yi JN, Jian LZ, et al. 2005. Co-expression with IFN-α HIV-1 gp120 recombinant fowlpox virus-specific CTL induced by the initial research. J Immunol Chin 21:254-256.
23. Zwick MB, Burton DR. 2007. HIV-1 neutralization: mechanisms and relevance to vaccine design. Curr HIV Res 5:608-624.